All the news Showing 10 of 10 articles from: New and experimental therapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... Hepatitis B capsid inhibitors look promising in early studies Liz Highleyman / 18 April 2018 Two experimental drugs that interfere with assembly of the hepatitis B virus (HBV) capsid and prevent production of functional new virus demonstrated good safety and promising antiviral activity in early clinical trials, according ... GS-4774 therapeutic vaccine shows little efficacy in people with hepatitis B Liz Highleyman / 08 December 2016 An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well tolerated but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, ... Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones Liz Highleyman / 15 November 2016 Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ... New Tenofovir Formulation Provides Safer Hepatitis B Treatment Medscape (free registration required) / 03 October 2016 Core inhibitor NVR 3-778 plus pegylated interferon inhibits hepatitis B activity Liz Highleyman / 05 May 2016 NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA and hepatitis B 'e' antigen (HBeAg), showing greater activity when ... REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infection Liz Highleyman / 16 November 2015 The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load and increased anti-HBs antibody titres, according ... Johnson and Johnson acquires Novira to expand HBV pipeline Healio Hepatology / 11 November 2015 Novel Therapeutic Approches to Cure Chronic HBV Infection EASL / 26 April 2013 Arrowhead data demonstrates RNAi candidate ARC-520 silences hepatitis B virus Arrowhead Research Corp press release / 27 February 2013 ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV New and experimental therapies Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds